予測・予兆検査の世界市場レポート 2025年

予測・予兆検査市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1％で84億7,000万米ドルに成長します。予測期間の成長は、疾病の早期発見に対する需要の増加、バイオテクノロジーとゲノミクスへの投資の増加、非侵襲的な検査方法に対する需要の高まり、高齢者人口の増加、精密医療への取り組みの拡大などに起因しています。予測期間における主な動向には、個別化医療の採用、家庭用検査キットの採用、ゲノミクスとビッグデータの統合、次世代シーケンシング（NGS）技術の開発、医薬品開発における予測検査の導入などがあります。

遺伝性疾患の有病率の増加は、今後の予測・予兆検査市場の拡大を促進すると予想されます。遺伝子の突然変異や染色体の変化など、デオキシリボ核酸（DNA）の異常によって引き起こされる遺伝性疾患には、嚢胞性線維症やダウン症候群などの疾患が含まれます。これらの疾患の罹患率増加の要因としては、母親の高年齢化、環境の影響、診断技術の向上などが挙げられます。予測・予兆検査は、症状が現れる前にリスクのある個人を特定することで、遺伝性疾患の発生を減らすために不可欠です。このプロアクティブな戦略により、早期介入やライフスタイルの変更が可能になり、これらの疾患の予防や重症度の軽減に役立ちます。例えば、2023年6月、米国を拠点とする非営利の医学・科学団体である米国遺伝子細胞治療学会は、2023年第3四半期に第III相臨床試験中の遺伝子治療薬の数が10％増加したと報告し、これは2022年第3四半期以来の四半期ごとの増加となりました。このように、遺伝性疾患の有病率の増加が予測・予兆検査市場の成長を促進しています。

予測・予兆検査市場の主要企業は、早期発見を改善し、個別化された健康洞察を提供するために、マイクロバイオーム駆動型予測モデルなどの技術的進歩を優先しています。これらの予測モデルは、マイクロバイオームデータを活用して潜在的な健康問題を予測し、早期診断を強化します。例えば2023年12月、インドのバイオテクノロジー企業Genefitletics社は、画期的な心血管疾患（CVD）予測モデルであるvascomathを発表しました。このモデルは、腸内・口腔マイクロバイオームからの遺伝子発現データを活用し、心血管リスクを早期に検出します。このモデルは既存の予測モデルと統合され、精密な栄養介入を提供するもので、予測・予兆検査における主要なイノベーションを象徴するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界予測・予兆検査PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の予測・予兆検査市場：成長率分析
• 世界の予測・予兆検査市場の実績：規模と成長, 2019-2024
• 世界の予測・予兆検査市場の予測：規模と成長, 2024-2029, 2034F
• 世界予測・予兆検査総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の予測・予兆検査市場テストの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 予測テスト
• 発症前検査
• 世界の予測・予兆検査市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん遺伝子検査
• 心血管遺伝子検査
• 神経学的遺伝子検査
• その他の用途
• 世界の予測・予兆検査市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断検査室
• 調査機関
• その他のエンドユーザー
• 世界の予測・予兆検査市場予測テストの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 遺伝性疾患の遺伝子検査
• がんリスク予測
• 心血管疾患の予測
• 神経変性疾患リスク予測
• 常染色体優性疾患の遺伝子スクリーニング
• 出生前予測検査
• 薬理ゲノム検査
• 世界の予測・予兆検査市場、検査の種類による発症前検査のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• ハンチントン病検査
• 遺伝性がんリスク検査
• 嚢胞性線維症の発症前検査
• 早期発症アルツハイマー病検査
• 遺伝性疾患の保因者スクリーニング
• 神経変性疾患の早期兆候の検査
• 家族性疾患の発症前遺伝子検査

第7章 地域別・国別分析

• 世界の予測・予兆検査市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の予測・予兆検査市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 予測・予兆検査市場：競合情勢
• 予測・予兆検査市場：企業プロファイル
  • F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • Quest Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Bio-Rad Laboratories Inc.
• Qiagen N.V.
• Peter MacCallum Cancer Centre
• Myriad Genetics Inc.
• SomaLogic Inc.
• Siteman Cancer Center
• Dante Labs S.R.L.
• Mapmygenome
• Manipal Health Enterprises
• Gene Vision
• Reliance Diagnostic
• GenepoweRx
• Personal Genomics
• Apollo Hospitals Enterprise Limited
• Cardio Diagnostics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 予測・予兆検査市場2029：新たな機会を提供する国
• 予測・予兆検査市場2029：新たな機会を提供するセグメント
• 予測・予兆検査市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Predictive and presymptomatic testing are genetic tests aimed at evaluating an individual's likelihood of developing a disease before any symptoms appear, particularly for inherited conditions. These tests help identify individuals at a higher risk for specific genetic disorders, allowing for early intervention and personalized care. The advantages include early diagnosis, customized prevention strategies, and more informed lifestyle decisions.

The primary forms of testing are predictive and presymptomatic. Predictive testing determines whether an individual has a genetic predisposition to develop a specific condition or disease in the future, even if they currently have no symptoms. Applications include cancer genetic testing, cardiovascular genetic testing, neurological genetic testing, and more. These tests are used by hospitals and clinics, diagnostic laboratories, research institutes, and other healthcare providers.

The predictive and presymptomatic testing market research report is one of a series of new reports from The Business Research Company that provides predictive and presymptomatic testing market statistics, including predictive and presymptomatic testing industry global market size, regional shares, competitors with a predictive and presymptomatic testing market share, detailed predictive and presymptomatic testing market segments, market trends and opportunities, and any further data you may need to thrive in the predictive and presymptomatic testing industry. This predictive and presymptomatic testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The predictive and presymptomatic testing market size has grown rapidly in recent years. It will grow from $5.24 billion in 2024 to $5.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.3%. The growth in the historic period can be attributed to increasing incidence of genetic disorders, rising demand for early diagnosis of chronic diseases, rising prevalence of cancer, increasing adoption of personalized medicine, increasing availability of direct-to-consumer genetic tests.

The predictive and presymptomatic testing market size is expected to see rapid growth in the next few years. It will grow to $8.47 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to increasing demand for early disease detection, increasing investments in biotechnology and genomics, rising demand for non-invasive testing methods, growth in the geriatric population, growth in precision medicine initiatives. Major trends in the forecast period include adoption of personalized medicine, adoption of home testing kits, integration of genomics and big data, development of next generation sequencing (NGS) technologies, implementation of predictive testing in drug development.

The growing prevalence of genetic disorders is expected to drive the expansion of the predictive and presymptomatic testing market in the future. Genetic disorders, caused by abnormalities in deoxyribonucleic acid (DNA) such as gene mutations and chromosome changes, include conditions like cystic fibrosis and Down syndrome. Factors contributing to the increasing incidence of these disorders include advanced maternal age, environmental influences, and improved diagnostic techniques. Predictive and presymptomatic testing is essential in reducing the occurrence of genetic disorders by identifying individuals at risk before symptoms appear. This proactive strategy enables early interventions or lifestyle changes that can help prevent or lessen the severity of these conditions. For example, in June 2023, the American Society of Gene and Cell Therapy, a US-based non-profit medical and scientific organization, reported a 10% increase in the number of gene therapies in Phase III clinical trials in the third quarter of 2023, marking the first quarterly rise since the third quarter of 2022. Thus, the increasing prevalence of genetic disorders is fueling the growth of the predictive and presymptomatic testing market.

Key companies in the predictive and presymptomatic testing market are prioritizing technological advancements, such as microbiome-driven predictive models, to improve early detection and offer personalized health insights. These predictive models utilize microbiome data to anticipate potential health issues and enhance early diagnosis. For example, in December 2023, Genefitletics, an Indian biotechnology firm, introduced vascomath, a groundbreaking cardiovascular disease (CVD) prediction model. This model leverages gene expression data from the gut and oral microbiome to detect cardiovascular risks early. It integrates with existing predictive models and provides precision nutrition interventions, representing a major innovation in predictive and presymptomatic testing.

In November 2022, Myriad Genetics, a US-based biotechnology company, acquired Gateway Genomics for an undisclosed sum. This acquisition aims to broaden Myriad's genetic testing portfolio and strengthen its position in the consumer genetics market. Gateway Genomics, also a US-based biotechnology firm, specializes in direct-to-consumer genetic testing and reproductive health solutions.

Major companies operating in the predictive and presymptomatic testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Mayo Clinic, Quest Diagnostics Inc., Illumina Inc., Bio-Rad Laboratories Inc., Qiagen N.V., Peter MacCallum Cancer Centre, Myriad Genetics Inc., SomaLogic Inc., Siteman Cancer Center, Dante Labs S.R.L., Mapmygenome, Manipal Health Enterprises, Gene Vision, Reliance Diagnostic, GenepoweRx, Personal Genomics, Apollo Hospitals Enterprise Limited, Cardio Diagnostics Inc.

North America was the largest region in the predictive and presymptomatic testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the predictive and presymptomatic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the predictive and presymptomatic testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The predictive and presymptomatic testing market consists of revenues earned by entities by providing services such as genetic testing, risk assessment, early disease detection, biomarker testing, and predictive modelling. The market value includes the value of related goods sold by the service provider or included within the service offering. The predictive and presymptomatic testing market also includes sales of carrier screening tests, genetic tests, diagnostic tools, prenatal testing kits, and Alzheimer's disease biomarkers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Predictive And Presymptomatic Testing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on predictive and presymptomatic testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for predictive and presymptomatic testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The predictive and presymptomatic testing market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Test Type: Predictive Testing; Presymptomatic Testing
• 2) By Application: Cancer Genetic Testing; Cardiovascular Genetic Testing; Neurological Genetic Testing; Other Applications
• 3) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutes; Other End Users
• Subsegments:
• 1) By Predictive Testing: Genetic Testing for Inherited Conditions; Cancer Risk Prediction; Cardiovascular Disease Prediction; Neurodegenerative Disease Risk Prediction; Genetic Screening for Autosomal Dominant Disorders; Prenatal Predictive Testing; Pharmacogenomic Testing
• 2) By Presymptomatic Testing: Huntington's Disease Testing; Hereditary Cancer Risk Testing; Cystic Fibrosis Presymptomatic Testing; Early-Onset Alzheimer's Disease Testing; Carrier Screening for Genetic Conditions; Testing for Early Signs of Neurodegenerative Diseases; Presymptomatic Genetic Testing for Familial Diseases
• Companies Mentioned: F. Hoffmann-La Roche AG; Thermo Fisher Scientific Inc.; Mayo Clinic; Quest Diagnostics Inc.; Illumina Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Predictive And Presymptomatic Testing Market Characteristics

3. Predictive And Presymptomatic Testing Market Trends And Strategies

4. Predictive And Presymptomatic Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Predictive And Presymptomatic Testing Growth Analysis And Strategic Analysis Framework

• 5.1. Global Predictive And Presymptomatic Testing PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Predictive And Presymptomatic Testing Market Growth Rate Analysis
• 5.4. Global Predictive And Presymptomatic Testing Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Predictive And Presymptomatic Testing Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Predictive And Presymptomatic Testing Total Addressable Market (TAM)

6. Predictive And Presymptomatic Testing Market Segmentation

• 6.1. Global Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Predictive Testing
• Presymptomatic Testing
• 6.2. Global Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Genetic Testing
• Cardiovascular Genetic Testing
• Neurological Genetic Testing
• Other Applications
• 6.3. Global Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic Laboratories
• Research Institutes
• Other End Users
• 6.4. Global Predictive And Presymptomatic Testing Market, Sub-Segmentation Of Predictive Testing, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Genetic Testing for Inherited Conditions
• Cancer Risk Prediction
• Cardiovascular Disease Prediction
• Neurodegenerative Disease Risk Prediction
• Genetic Screening for Autosomal Dominant Disorders
• Prenatal Predictive Testing
• Pharmacogenomic Testing
• 6.5. Global Predictive And Presymptomatic Testing Market, Sub-Segmentation Of Presymptomatic Testing, By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Huntington's Disease Testing
• Hereditary Cancer Risk Testing
• Cystic Fibrosis Presymptomatic Testing
• Early-Onset Alzheimer's Disease Testing
• Carrier Screening for Genetic Conditions
• Testing for Early Signs of Neurodegenerative Diseases
• Presymptomatic Genetic Testing for Familial Diseases

7. Predictive And Presymptomatic Testing Market Regional And Country Analysis

• 7.1. Global Predictive And Presymptomatic Testing Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Predictive And Presymptomatic Testing Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Predictive And Presymptomatic Testing Market

• 8.1. Asia-Pacific Predictive And Presymptomatic Testing Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Predictive And Presymptomatic Testing Market

• 9.1. China Predictive And Presymptomatic Testing Market Overview
• 9.2. China Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Predictive And Presymptomatic Testing Market

• 10.1. India Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Predictive And Presymptomatic Testing Market

• 11.1. Japan Predictive And Presymptomatic Testing Market Overview
• 11.2. Japan Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Predictive And Presymptomatic Testing Market

• 12.1. Australia Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Predictive And Presymptomatic Testing Market

• 13.1. Indonesia Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Predictive And Presymptomatic Testing Market

• 14.1. South Korea Predictive And Presymptomatic Testing Market Overview
• 14.2. South Korea Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Predictive And Presymptomatic Testing Market

• 15.1. Western Europe Predictive And Presymptomatic Testing Market Overview
• 15.2. Western Europe Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Predictive And Presymptomatic Testing Market

• 16.1. UK Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Predictive And Presymptomatic Testing Market

• 17.1. Germany Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Predictive And Presymptomatic Testing Market

• 18.1. France Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Predictive And Presymptomatic Testing Market

• 19.1. Italy Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Predictive And Presymptomatic Testing Market

• 20.1. Spain Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Predictive And Presymptomatic Testing Market

• 21.1. Eastern Europe Predictive And Presymptomatic Testing Market Overview
• 21.2. Eastern Europe Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Predictive And Presymptomatic Testing Market

• 22.1. Russia Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Predictive And Presymptomatic Testing Market

• 23.1. North America Predictive And Presymptomatic Testing Market Overview
• 23.2. North America Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Predictive And Presymptomatic Testing Market

• 24.1. USA Predictive And Presymptomatic Testing Market Overview
• 24.2. USA Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Predictive And Presymptomatic Testing Market

• 25.1. Canada Predictive And Presymptomatic Testing Market Overview
• 25.2. Canada Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Predictive And Presymptomatic Testing Market

• 26.1. South America Predictive And Presymptomatic Testing Market Overview
• 26.2. South America Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Predictive And Presymptomatic Testing Market

• 27.1. Brazil Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Predictive And Presymptomatic Testing Market

• 28.1. Middle East Predictive And Presymptomatic Testing Market Overview
• 28.2. Middle East Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Predictive And Presymptomatic Testing Market

• 29.1. Africa Predictive And Presymptomatic Testing Market Overview
• 29.2. Africa Predictive And Presymptomatic Testing Market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Predictive And Presymptomatic Testing Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Predictive And Presymptomatic Testing Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Predictive And Presymptomatic Testing Market Competitive Landscape And Company Profiles

• 30.1. Predictive And Presymptomatic Testing Market Competitive Landscape
• 30.2. Predictive And Presymptomatic Testing Market Company Profiles
  • 30.2.1. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Mayo Clinic Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Quest Diagnostics Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Predictive And Presymptomatic Testing Market Other Major And Innovative Companies

• 31.1. Bio-Rad Laboratories Inc.
• 31.2. Qiagen N.V.
• 31.3. Peter MacCallum Cancer Centre
• 31.4. Myriad Genetics Inc.
• 31.5. SomaLogic Inc.
• 31.6. Siteman Cancer Center
• 31.7. Dante Labs S.R.L.
• 31.8. Mapmygenome
• 31.9. Manipal Health Enterprises
• 31.10. Gene Vision
• 31.11. Reliance Diagnostic
• 31.12. GenepoweRx
• 31.13. Personal Genomics
• 31.14. Apollo Hospitals Enterprise Limited
• 31.15. Cardio Diagnostics Inc.

32. Global Predictive And Presymptomatic Testing Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Predictive And Presymptomatic Testing Market

34. Recent Developments In The Predictive And Presymptomatic Testing Market

35. Predictive And Presymptomatic Testing Market High Potential Countries, Segments and Strategies

• 35.1 Predictive And Presymptomatic Testing Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Predictive And Presymptomatic Testing Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Predictive And Presymptomatic Testing Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250423_r33524_Predictive_And_Presymptomatic_Testing_GMR_2025